Receptor News and Research

RSS

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Columbia University will award the 2014 Louisa Gross Horwitz Prize to James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center, for his work on understanding the process of T-cell activation and for developing therapies that harness the immune system to fight cancer.

3 Oct 2014

Ganymed, BioNTech AG open new headquarters and research facility in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. 10,000 square-meters (108,000 square-feet) headquarters and research facility.

1 Oct 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

The Brain & Behavior Research Foundation will honor eight scientists with its 2014 Outstanding Achievement Prizes for work delving into psychiatric disorders that affect one in four people. The awards, which celebrate the transformative power of neuroscience and psychiatric research to improve the lives of people with mental illness, will be presented at the Foundation's National Awards Dinner at the Pierre Hotel.

30 Sep 2014

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Survey: Many patients not always well informed about treatment options

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs. The researchers say the work reveals new targets for breast cancer therapy and will help doctors predict which patients need the most aggressive treatment.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.

26 Sep 2014

New approach to create treatments for osteoporosis, autoimmune diseases

Scientists have developed an approach to creating treatments for osteoporosis and autoimmune diseases that may avoid the risk of infection and cancer posed by some current medications.

26 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Genetic factors influence consumption of alcoholic beverages

How people perceive and taste alcohol depends on genetic factors, and that influences whether they "like" and consume alcoholic beverages, according to researchers in Penn State's College of Agricultural Sciences.

25 Sep 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer.

24 Sep 2014

Mfn2 protein: A future therapeutic target for neuronal death reduction in ischemic stroke

A new study published in the prestigious publication The EMBO Journal shows that the mitochondrial protein Mfn2 may be a future therapeutic target for neuronal death reduction in the late phases of an ischemic stroke.

24 Sep 2014

Receptor News and Research

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Ganymed, BioNTech AG open new headquarters and research facility in Germany

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

Targeted treatments may improve idiopathic PAH survival

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Survey: Many patients not always well informed about treatment options

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

New approach to create treatments for osteoporosis, autoimmune diseases

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

NCCN ORP awards four research grants to advance development of nintedanib

Genetic factors influence consumption of alcoholic beverages

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

Mfn2 protein: A future therapeutic target for neuronal death reduction in ischemic stroke

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News